Globalization of Pediatric Drug Trials–For Whose Benefit?
There is no evidence to indicate that children have been the beneficiaries of the Pediatric Exclusivity Provision of FDAMA (enacted in 1998): there is evidence that pharmaceutical companies have increased their profits from the legislation by at least $14 billion.